Limitations of Animal Tests to Detect Sensitization Reactions in Man by G E Paget MD (Macclesfield)
As a basis for my consideration of the limitations of animal tests for the detection of sensitizing potentialities in drugs intended for human use I shall first consider the nature of the reliance which we place on animal tests for the detection of other biological properties of chemical substances. Much of my paper is an elaboration of what is obvious to anybody who is in contact with, or has experience of, such tests. My justification for this must be that few members of the medical profession have such experience.
In general the proliferation of drugs for the treatment of human disease seen in the last few decades has only been possible because a large variety of tests in experimental animals has been shown empirically to correlate reasonably well with various human disease situations. The aim of any biologist arranging an animal test for the detection of actions which it is hoped will be of therapeutic worth in man is to employ a test or battery of tests whose correlation with human experience is as close to unity as possible. In these circumstances the wise pharmacologist will first acquaint himself with what is known of the target disease in human beings. He must consider what is known of the etiology of the disease, of its pathogenesis, and of its manifestations. It is plain that we have immediately encountered a major hurdle in the design of a screening test supposedly resembling almost any human disease, since in no case is both the etiology of a human disease fully understood and its pathogenesis unravelled. Nevertheless in a substantial number of diseases sufficient is known of the etiology and pathogenesis to form a useful background for the design of a screening test.
Perhaps the simplest of such cases are those involving an infectious agent producing a welldefined condition in a human host. Under these circumstances it may be possible to produce a screening test which corresponds very precisely with the human disease. Where such a screening test can be used it may be anticipated that there will be a very close correspondence between the effects of a drug brought intact to the site of action in an animal and the effects of the same drug brought intact to the site of action in a human being. The unreliability of the test in such circumstances will arise from species differences in the absorption, metabolism and transport of the drug.
Unfortunately this ideal screening test is rarely achieved in practice. More commonly major variations from the human disease must be accepted in the animal disease used as a screening mechanism. Thus, mice infected with tubercle bacilli show a disease very different from human tuberculosis, but nevertheless mouse tuberculosis can be used with moderate reliability as a method of predicting antituberculous action of drugs in man. Here unreliability may stem not only from differences in the metabolism and transport of the drug but also from inherent differences between mouse and man in the disease process.
Even more remote experimental situations may be used predictively. Thus no pharmacologist would pretend that a cat anmsthetized with pentobarbitone sodium and connected by multiple levers and manometers to various pieces of electronic apparatus resembles in any way a human with hypertension. Since neither the etiology nor the pathogenesis of human hypertension is understood sufficiently for a more rational screening method to be designed it seems legitimate to look for drugs which depress the blood pressure of the an&asthetized cat in the hope, frequently fulfilled, that they will depress the blood pressure of hypertensive human beings. It is also legitimate, where actions on fundamental biological processes are concerned, to use even less immediately relevant screening tests. Thus, when one is looking for antimitotic actions, an initial screening test using the growing roots of the broad bean may furnish a sufficient degree of reliable predictiveness, and it has even been proposed that the behaviour of spiders or Siamese fighting fish be used as a screening method for drugs which it is hoped might affect human behaviour. Here the connexion is so remote that intuitively one feels that little reliance can be placed on results obtained in this way.
A further complication arises when we consider the question of screening compounds for undesirable actions. Here we must introduce an assumption concerning the nature of responses to increasing doses. In all toxicity screening the assumption is made that variation in response to a given dose of a drug between individual members of a species is due to varying susceptibility to the drug and that, irrespective of such variations, a dose will exist at which, in any species, the proportion of individuals showing the undesirable action will be negligibly small, and a dose will exist at which all members of the species will show such a reaction. It is also assumed that, apart from these quantitative differences, the qualitative 9 nature of the undesirable action will be the same in both cases. It is therefore possible, by observing the effects ofvery large doses on all the individuals receiving such doses, to make what is hoped will be meaningful predictions about the nature of possible toxic actions even though quantitative experiments suggest that the incidence of such actions will be low.
Again it can be shown empirically that these assumptions are reliable sufficiently often for the tests to have some useful meaning. Nevertheless such tests are beset by species variation to a large degree. Such variations probably arise for the most part from differences in absorption, transport and metabolism of the drug but also to some degree from variations in the biological reactivity of the target organ.
It can be seen from my discussion so far that the design of screening tests for most biological properties of chemical compounds depends on some knowledge of the target condition in human beings and on the validity of certain assumptions. We must now consider whether the same approach is possible in the design of screening tests for the detection of sensitizing properties. We have seen how in most circumstances the best possible screening test is that which resembles the human situation most closely. Indeed there can be no doubt, for most purposes, experimental groups of human beings would furnish the most precisely predictive results. When we consider hypersensitivity we see that such an approach must fail, since, although no precise figures for the incidence of sensitization reactions can be obtained even for compounds known to produce this phenomenon, it is clear that this incidence is extremely small. To detect whether a compound related to aspirin is a more or less potent sensitizer in man would require that it be administered to several thousand individuals at least. Since transferring data from animals to man must involve, even under the most ideal situations, several causes for uncertainty such figures would require several-fold multiplication even if animals responded exactly as human beings to the agent in question. So far as I know no investigation has ever been performed in which groups of laboratory animals numbering tens of thousands have been used.
A similar situation exists in respect of many more conventional toxic actions. In this case, as we have seen, a dose-response relationship is assumed and effects at lower doses are extrapolated from changes found in animals given very large doses. This approach likewise cannot be used to detect sensitivity reactions since the most certain clinical observation in this field is that no dose-response relationship exists between sensitivity phenomena and the amount of substance required to elicit them.
Since these simple approaches to the design of an animal test are impracticable, some enquiry must be made into the nature of the individual susceptibility demonstrated by some human beings in the hope that the clinical data will enable animals to be modified to resemble such specially susceptible human beings. Unfortunately studies of the natural history of sensitization phenomena in man are completely lacking. It is not known whether susceptibility to drug sensitization is genetically determined; whether it varies with age or sex, or geographical location; whether individuals showing such susceptibility to one drug will show it to other and completely different drugs. It is not even known whether an individual who readily displays contact sensitization to streptomycin is more likely to suffer from polyarteritis nodosa after administration of a sulphonamide than an individual who is resistant to contact sensitization. No test will distinguish between individuals showing hypersensitivity to a drug and the normal population except administration of that drug.
This list of ignorances could be prolonged to cover virtually every important biological question involved in the occurrence of drug sensitization in man. The very concept of hypersensitivity displays a certain haziness at the edges, since it includes clinical conditions of widely differing manifestations and severity and completely uncertain interrelationships. At one end of the scale occurs the troublesome and inconvenient contact dermatitis affecting nurses using streptomycin, and at the other the lethal blood dyscrasias occurring in a small proportion of individuals taking certain sulphonamides, analgesics and other drugs. In some texts certain diseases are described as due to drug sensitization, as for example polyarteritis nodosa, while in other texts this possibility is discounted or ignored. Some unusual reactions to drugs start by being considered as sensitization phenomena, for example cholestatic jaundice due to chlorpromazine, and then without any apparent increase in knowledge about the pathogenesis of the condition opinion veers until it is considered to be a more conventional toxic action.
Publications on the subject of sensitization to drugs often derive from individuals with immunological interests. For many conditions which occur following the administration of drugs this is the only evidence of their immunological nature. In fact, in most of the syndromes of drug sensitization detectable circulating antibodies are not commonly found, nor are other common measures of immunological response constantly present.
This rather biased and critical discussion ofour knowledge of human hypersensitivity to drugs does suggest that this knowledge is so inadequate that no possibility of designing a screening test which mimics the clinical situation at all closely can as yet be considered. Not surprisingly the experimental work so far published does little to elucidate these obscurities. First examination of the experimental work discloses the surprising fact that the only sensitization phenomenon which has been reliably and indisputably produced in experimental animals is skin sensitization brought about in various ways by direct contact of the drug with the animal's skin, and that the more important blood dyscrasias, liver disorders, asthmas, arteriopathies and arthropathies have not been produced experimentally by drugs known to produce such lesions in human beings. The most illuminating recent work, which will be discussed in more detail by Mr Davies (below), is that concerned with contact sensitization to penicillin (De Weck & Eisen 1960 , Levine 1960 . Here it seems that a metabolite, penicillenic acid, may be important in the production of contact sensitivity and that animals sensitized to this substance show cross-sensitivity to penicillin. Very probably such animals might be used to predict whether a new penicillin would cause sensitization phenomena in individuals already sensitized to older penicillins and a knowledge of this mechanism might be used to predict whether such a new penicillin would, of itself, give rise to sensitization in this way. It would not, however, give any assurance that some other metabolite might not be involved in the case of a new penicillin or that it will not cause any other variety of sensitization phenomena, and of course if one is not interested in penicillin sensitivity the screening test is of no more than considerable academic interest. If we consider the more general implications and accept the thesis that penicillenic acid is the metabolite responsible for human hypersensitivity to penicillin, it becomes of interest to enquire whether other species than man produce this substance. In fact this interesting information does not appear to be available. Mr Davies will discuss the possibility that in many other cases of hypersensitivity, a metabolite rather than the drug itself may be responsible for the unusual reaction encountered. We know that the metabolism of drugs does vary from species to species and striking examples of this are familiar. Such variation is of importance as a major cause of species differences in both therapeutic and toxic actions of drugs. Indeed in our own laboratories the vast majority of species differences encountered have proved, when adequately investigated, to be due to this cause rather than to differences in the sensitivity of the target organ. If metabolites are indeed important in the genesis of hypersensitivity reactions in man, the work involved in investigating a new drug for its potentialities in this respect is immediately multiplied fiveor ten-fold, even if some suitable screening system were to exist; since clearly not only those metabolites known to occur in experimental animals must be investigated but also all conceivable metabolites which might arise in human beings.
It is clear from the foregoing that at the moment there is no prospect whatsoever of setting up even a remotely relevant screening test for the detection of the sensitizing potential in new drugs. Indications exist that in some special circumstances screening tests of limited applicability may be devised but even such tests are probably of doubtful predictive reliability. To this extent, therefore, I have shown that animal tests do have their limitations in this respect and that these limitations are serious. I hope that I have also shown that these limitations essentially arise from our nebulous knowledge of the factors involved in human cases of hypersensitivity and that satisfactory animal tests in this field, as indeed all other fields in which they are used, can only be designed when a sufficient body of knowledge accumulates about the human condition which they are intended to model. Until such knowledge is available it is idle to consider the establishment of such tests.
Prospects for Animal Tests in Experimental Sensitization to Drugs by G E Davies BSC (Macclesfield)
Dr Paget (p 9) has emphasized the limitations of animal tests in work on drug hypersensitivity and has concluded, justifiably, that at present such tests have no predictive value. This paper sets out to examine critically what has been done and to suggest, with a deliberate bias towards optimism, what more might be done. These considerations themselves have limitations imposed by a lack of definition of the term 'drug hypersensitivity'. I
